Dopamine Agonists: all 968 studies that test it
Page 10 of 10. Open to participants first (53), then studies with results posted, then the rest; newest registration first within each.
- Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietyCompletedNCT00177008Phase 4
- Aripiprazole Treatment of the ProdromeTerminatedNCT00169949Not applicable
- Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot StudyCompletedNCT00167817Phase 4
- Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's DiseaseCompletedNCT00153972Phase 4
- Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs SyndromeCompletedNCT00152997Phase 2
- A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)CompletedNCT00152958Phase 3
- A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.CompletedNCT00145171Phase 3
- Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs SyndromeCompletedNCT00144209Phase 3
- Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United StatesCompletedNCT00143026Phase 4
- Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's DiseaseCompletedNCT00142545Phase 3
- A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's DiseaseCompletedNCT00139880Phase 3
- A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's DiseaseCompletedNCT00139867Phase 3
- Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg SyndromeCompletedNCT00136045Phase 3
- Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs SyndromeCompletedNCT00135993Phase 3
- A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/LevodopaCompletedNCT00134966Phase 3
- Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's DiseaseCompletedNCT00134251Phase 3
- Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)CompletedNCT00133198Phase 3
- Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's DiseaseCompletedNCT00129181Not applicable
- An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac SurgeryCompletedNCT00122018Phase 2
- Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsiaStatus unknownNCT00117546Phase 4
- Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT00116259Not applicable
- Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With DyslexiaStatus unknownNCT00111371Phase 4
- Improved Language Acquisition With LevodopaCompletedNCT00103805Phase 4
- Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With SchizophreniaCompletedNCT00103571Phase 4
- Dopaminergic Enhancement of Learning and Memory in AphasiaCompletedNCT00102869Phase 4
- Aripiprazole Oral Acceptability TrialCompletedNCT00101569Phase 3
- Assessment of Potential Interactions Between GBR 12909 and Cocaine - 1Status unknownNCT00100113Phase 1
- Study of Aripiprazole in Patients With Acute Bipolar ManiaCompletedNCT00097266Phase 3
- Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's DiseaseCompletedNCT00096720Phase 2
- A Study of Adjunctive Aripiprazole in Patients With Major Depressive DisorderCompletedNCT00095823Phase 3
- Aripiprazole in Patients With Psychosis Associated With Parkinson's DiseaseCompletedNCT00095810Phase 4
- A Study of Adjunctive Aripiprazole in Participants With Major Depressive DisorderCompletedNCT00095758Phase 3
- Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With DementiaCompletedNCT00095719Phase 3
- Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective DisorderCompletedNCT00095524Phase 3
- Aripiprazole in Patients With Acute ManiaCompletedNCT00095511Phase 3
- A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive EpisodeCompletedNCT00094432Phase 3
- GBR 12909 Study in Cocaine Experienced African American Volunteers - 1Status unknownNCT00089687Phase 1
- Assessment of Interactions Between Methamphetamine and Aripiprazole - 1Status unknownNCT00089440Phase 1
- Study of Olanzapine vs. Aripiprazole in the Treatment of SchizophreniaCompletedNCT00088049Phase 4
- Study of Aripiprazole in Subjects With AlcoholismCompletedNCT00082199Phase 4
- Study of Three Doses of Aripiprazole in Patients With Acute SchizophreniaCompletedNCT00080327Phase 4
- Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression EpisodeCompletedNCT00080314Phase 3
- Levetiracetam Treatment of L-dopa Induced DyskinesiasCompletedNCT00076674Phase 2
- Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's DiseaseCompletedNCT00058838Phase 3
- An 8 Week Depression Study In Adults Diagnosed With Major Depressive DisorderCompletedNCT00057239Phase 2
- An 8 Week Study Of Adults Diagnosed With Major Depressive DisorderCompletedNCT00057226Phase 2
- An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive DisorderCompletedNCT00057213Phase 2
- Assessment of the Potential Interactions Between Cocaine and GBR 12909 - 1Status unknownNCT00051896Phase 1
- Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar DisorderCompletedNCT00046384Phase 3
- Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeCompletedNCT00041678Phase 3
- Broad Effectiveness: Study With AripiprazoleCompletedNCT00036361Phase 3
- Study of Aripiprazole in Patients With a History of Bipolar DisorderCompletedNCT00036348Phase 3
- Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.CompletedNCT00036218Phase 3
- Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's DiseaseTerminatedNCT00036205Phase 3
- Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic DisordersCompletedNCT00036127Phase 2/3
- Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeCompletedNCT00036114Phase 3
- Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar DisorderCompletedNCT00036101Phase 3
- A Study of Cabergoline for the Treatment of Cocaine Dependence - 1CompletedNCT00033111Phase 2
- Clinical Trial of Pramipexole in Bipolar DepressionCompletedNCT00025792Phase 2
- Riluzole to Treat Parkinson's DiseaseCompletedNCT00013624Phase 2
- Timing of Levodopa Treatment in Parkinson's DiseaseCompletedNCT00004733Phase 3
- Randomized Study of Pergolide in Children With Tourette SyndromeCompletedNCT00004433Not applicable
- Treatment of Parkinson's Disease With a Transdermal Skin PatchCompletedNCT00001931Phase 2
- Infusion Laboratory: Protocol 4 (Dihydrexidine) - 13Status unknownNCT00000348Phase 1
- Infusion Laboratory: Protocol 2 (Lisuride) - 3Status unknownNCT00000338Phase 1
- Pergolide Treatment for Substance Abusers - 4CompletedNCT00000269Phase 2
- Dose Response Trial of Pergolide for Cocaine Dependence - 1CompletedNCT00000248Phase 3
- IV Cocaine Abuse: A Laboratory Model - 4CompletedNCT00000215Phase 2